Author:Universal GravitationEditor: VitaminOn November 20, 2024, the National Medical Products Administration officially approved Zolitinib Hydrochloride Tablets (brand name: ), a Class 1 innovative drug jointly developed by Alpha Biopharma and AstraZeneca.Zerene) launched.
This innovative drug is specifically designed for adult patients with non-small cell lung cancer (NSCLC), particularly those harboring epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, and whose tumors have metastasized to the central nervous system (CNS), at locally advanced or metastatic stages. It serves as a first-line treatment option for such patients.This approval marks a new breakthrough in the field of lung cancer treatment in China.
Figure 1.Zolitinib Hydrochloride TabletsApprovedListed, ComeSource: NMPA official website
The Gradual Rise of ZolitinibIn 2017, Alpha Biopharma partnered with AstraZeneca to reach a collaborative agreement, introducing the leading candidate drug Zorifertinib for the treatment of brain metastases in lung cancer, achieving a breakthrough in precision therapy. This collaboration also marked the beginning of the development journey of Zorifertinib tablets.Zorifertinib (AZD3759) is a reversible oral epidermal growth factor receptor activating mutation (L858R and Exon 19Del) tyrosine kinase inhibitor (EGFR-TKI). It is specifically designed for the treatment of patients with advanced non-small cell lung cancer and central nervous system metastases. Unlike all other TKI drugs, it is not a substrate for the blood-brain barrier endothelial cell transport proteins P-gp and BCRP, and has the ability to completely cross the blood-brain barrier, maintaining high drug exposure in brain tissue and cerebrospinal fluid.2022 was a pivotal year for the development of Zoritini tablets. In August of the same year, Alpha Biopharma announced that the final visit of the last subject in its international multicenter Phase 2/3 clinical research project EVEREST had been successfully completed. The study was conducted across 55 research centers, including those in mainland China, Taiwan, South Korea, and Singapore, with a total of 492 patients with EGFR mutation-positive non-small cell lung cancer and central nervous system metastases enrolled in the study group. Previous clinical and preclinical data have both indicated,Zoritini demonstrates excellent blood-brain barrier penetration capabilities, showing significant advantages in treating central nervous system metastases in non-small cell lung cancer and enhancing overall efficacy, while maintaining...EGFR-TKISafety Characteristics of DrugsIn January 2023, Alpha Biopharma submitted a new drug application for Zolitinib Hydrochloride Tablets (Class 1 New Drug) and the application was accepted. During the research, development, and submission process of Zolitinib Hydrochloride Tablets, the pharmaceutical regulatory authorities played a crucial role. The Suzhou Inspection Branch of the Provincial Drug Administration and the Suzhou Branch of the Provincial Drug Evaluation and Inspection Center proactively engaged with the company, closely monitoring the progress of the drug's development and application. They actively identified and helped resolve key challenges encountered during the drug submission process, accelerating the drug’s path to market. After undergoing a rigorous evaluation process, the drug was recently approved for marketing.Characteristics and Advantages of ZolitinibNon-small cell lung cancer with central nervous system metastasis has always been a difficult point in treatment, mainly because the blood-brain barrier increases the difficulty of drug penetration into the brain.Zorifertinib hydrochloride tablets have the unique advantage of 100% penetration through the blood-brain barrier, allowing them to act more effectively on lesions during treatment.Compared with existing competitive drugs on the market, Zoritini Hydrochloride Tablets demonstrate advantages in the following aspects:
- First, it is the world's first next-generation EGFR-TKI that specifically targets EGFR gene-sensitive mutations and acts as a potent substrate for the non-blood-brain barrier efflux transporters P-gp and BCRP. This characteristic enables Zorifertinib Hydrochloride Tablets to fully penetrate the blood-brain barrier, generating and maintaining effective drug exposure in brain tissue and cerebrospinal fluid, thereby effectively treating advanced EGFR-sensitive mutation non-small cell lung cancer patients with central nervous system metastases.
- Secondly, Zorifertinib Hydrochloride Tablets have demonstrated significant efficacy and safety in clinical trials. Compared with first-generation EGFR TKIs (such as Gefitinib or Erlotinib), Zorifertinib Hydrochloride Tablets exhibit better intracranial and systemic antitumor activity in patients with central nervous system metastases and EGFR-sensitive mutations in advanced NSCLC. This advantage allows Zorifertinib Hydrochloride Tablets to achieve higher response rates and longer durations when treating NSCLC patients with CNS metastases.
- In addition, Zorifertinib Hydrochloride Tablets also demonstrate significant advantages in terms of drug resistance. Due to its ability to specifically bind to EGFR mutation sites, thereby inhibiting the proliferation of tumor cells, it shows remarkable effects in combating resistance to targeted drugs.
Clinical Data of Zolitinib Hydrochloride Tablets is Encouraging. In clinical trials, the drug demonstrated significant efficacy and safety.Results from a study presented at the ASCO meeting showed that, compared with first-generation EGFR TKIs, zorifertinib hydrochloride tablets demonstrated better intracranial and systemic antitumor activity in patients with CNS metastases and EGFR-sensitive mutations in advanced NSCLC. Specific data are as follows:The median progression-free survival (PFS) was 9.6 months in the zorifertinib hydrochloride group and 6.9 months in the control group, with a 28% reduction in the risk of disease progression or death.The objective response rate (ORR) was 68.6% in the zolitinib hydrochloride group and 58.4% in the control group.The median duration of response (DoR) was 8.2 months in the zorifertinib hydrochloride group and 6.8 months in the control group.
In terms of the control of brain metastases, the Zorifertinib Hydrochloride group also demonstrated superior efficacy compared to the control group. The specific data is as follows:The results evaluated by BICR showed that the median PFS was 15.2 months in the zolitinib hydrochloride group and 8.3 months in the control group.The ORR of the Zorifertinib Hydrochloride group was 75.0%, compared to 64.2% in the control group.The DoR in the zolitinib hydrochloride group was 12.4 months, compared to 7.0 months in the control group.
In terms of safety, the incidence of treatment-related adverse events (TRAEs) of any grade was similar between the zolitini hydrochloride treatment group and the control group, but the incidence of TRAEs ≥ Grade 3 was slightly higher in the zolitini hydrochloride group. However, no new safety signals emerged during the study.This indicates that the safety of Zolitinib Hydrochloride Tablets in clinical application is acceptable.These data fully demonstrate the efficacy and safety of Zorifertinib Hydrochloride Tablets in treating NSCLC patients with EGFR-sensitive mutations accompanied by CNS metastases.The Market Value of ZolitinibFrom the perspective of market valuation, Zorifertinib Hydrochloride Tablets demonstrate significant market potential. Globally, lung cancer ranks among the top in both incidence and mortality among cancer types. According to data from the International Agency for Research on Cancer (IARC), there were 2.2 million new cases of lung cancer worldwide in 2019, with over 1.8 million deaths. This large patient population provides a broad market space for Zorifertinib Hydrochloride Tablets.
As a new generation of EGFR-TKI, Zorifertinib Hydrochloride Tablets have complete blood-brain barrier penetration capabilities, generating and maintaining effective drug exposure in brain tissue and cerebrospinal fluid. This feature gives it a unique advantage in treating EGFR mutation-positive NSCLC patients with CNS metastases.Currently, there are no other drugs on the market that can fully meet the needs of this patient population. Therefore, the launch of Zorifertinib Hydrochloride Tablets will fill this market gap.Zorifertinib Hydrochloride Tablets have demonstrated significant efficacy and safety in clinical trials, giving them a stronger competitive edge in the market. Compared with existing treatment options, Zorifertinib Hydrochloride Tablets show higher response rates, longer duration of effect, and good safety. These advantages will enable Zorifertinib Hydrochloride Tablets to occupy an important position in the field of lung cancer treatment. Market forecasts indicate that after its launch, Zorifertinib Hydrochloride Tablets will quickly capture the market and bring substantial economic returns to pharmaceutical companies.Zorifertinib Hydrochloride Tablets, as the world's first drug specifically developed for advanced non-small cell lung cancer with central nervous system metastasis to undergo registration clinical trials and achieve significant results, represent a major innovative breakthrough. The market launch of Zorifertinib Hydrochloride Tablets not only...Filled this fieldDomain Gap, andBrings New Treatment Options for Lung Cancer Patients。References:
1. National Medical Products Administration website
2. Research report released at the ASCO conference
*Disclaimer: This article merely introduces research progress in the pharmaceutical and disease fields, provides a brief overview of research, or shares pharmaceutical-related information. It does not recommend any treatment or diagnostic plans, nor does it constitute advice on related investments.If there are any omissions, please feel free to communicate and point them out!
